Comments
FDA extends review for Pfizer arthritis drug by three months
22.08.2012. | (Reuters) - The U.S. Food and Drug Administration extended by three months its review of Pfizer Inc's experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline....
